Effector Therapeutics
Solana Beach, US · Founded 2012 · Delaware corporation · 7 known investors
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
Biotech
Founders & leadership
SF
Stephen F. Worland, Ph.D.Executive Officer, Director
AM
Alana McNultyExecutive Officer
SG
Simeon GeorgeDirector
JR
Jonathan RootDirector
KH
Ken HaasDirector
LL
Laurence LaskyDirector
MG
Markus GoebelDirector
Investors · 7
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pfizer Venture Investments$5M – $20M
US Venture PartnersMenlo Park · $500K – $10M
Sofinnova VenturesreportedMenlo Park · $100K – $15Mvia Maha Katabi · board
Reported raises · per SEC filings
Form D private placements▶$20.4MraisedMay 2019 · 25 investors · BiotechnologyRule 506(b)
▶$20.4MraisedMay 2019 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denis Patrick, Ph.D.Director
- Stephen T. Worland, Ph.D.Executive Officer, Director
- John W. SmitherDirector
- Stefan Larson, Ph.D.Director
- Alana McNultyExecutive Officer
- David Maki, J.D.Director
- Jonathan D. Root, M.D.Director
- Kenneth Haas, J.D.Director
- Simeon J. George, M.D.Director
- Laurence Lasky, Ph.D.Director
- Offering amount
- $21.8M
- Amount sold
- $20.4M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedJul 2017 · 26 investors · BiotechnologyRule 506(b)
▶$16.8MraisedJul 2017 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan D. Root, M.D.Director
- Stephen T. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Jeremy Barton, M.D.Executive Officer
- Kenneth Haas, J.D.Director
- Simeon J. George, M.D.Director
- Maha Katabi, Ph.D.Director
- David Maki, J.D.Director
- Markus Goebel, M.D., Ph.D.Director
- Elaine Jones, Ph.D.Director
- Laurence Lasky, Ph.D.Director
- Offering amount
- $38.6M
- Amount sold
- $16.8M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56MraisedFeb 2016 · 20 investors · BiotechnologyRule 506(b)
▶$56MraisedFeb 2016 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ken HaasDirector
- Maha KatabiDirector
- Simeon GeorgeDirector
- David MakiDirector
- Laurence LaskyDirector
- Markus GoebelDirector
- Stephen T. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Jonathan RootDirector
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$36.2MraisedJul 2015 · 15 investors · BiotechnologyRule 506(b)
▶$36.2MraisedJul 2015 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen F. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Simeon GeorgeDirector
- Jonathan RootDirector
- Ken HaasDirector
- Laurence LaskyDirector
- Markus GoebelDirector
- Offering amount
- $57M
- Amount sold
- $36.2M
- First sale
- May 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.